BMT CTN myeloma intergroup workshop on minimal residual disease and immune profiling: summary and recommendations from the organizing committee

Holstein, S.A. (Sarah A.); Avet-Loiseau, H. (Herve); Hahn, T. (Theresa); Ho, C.M. (Christine M.); Lohr, J.G. (Jens G.); Munshi, N.C. (Nikhil C.); Paiva, B. (Bruno); Pasquini, M.C. (Marcelo C.); Tario-Jr, J.D. (Joseph D.); Usmani, S.Z. (Saad Z.); Wallace, P.K. (Paul K.); Weisel, K. (Katja); McCarthy, P.L. (Philip L.)

Keywords:

Minimal residual disease
Immune profiling
Multiple myeloma
Autologous stem cell transplant

Issue Date:

2018

Publisher:

Elsevier BV

Project:

2U10HL069294-11 - - Blood &Marrow Transplant Clinical Trials Network Data Coordinating Center
5R01HL107213-02 - - Ancillary Studies in Clinical Trials - PRIMeR

ISSN:

1083-8791

Citation:

Holstein, S.A. (Sarah A.); Avet-Loiseau, H. (Herve); Hahn, T. (Theresa); et al. "BMT CTN myeloma intergroup workshop on minimal residual disease and immune profiling: summary and recommendations from the organizing committee". Biology of blood and marrow transplantation. 24 (4), 2018, 641 - 648

Abstract

The Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling was convened on December 1, 2016 at the American Society of Hematology meeting to discuss the emerging data and technologies for minimal residual disease assessment and immune profiling in myeloma. Particular emphasis was placed on developing strategies to incorporate these techniques into clinical trial design. This document reviews the literature, summarizes the topics discussed in the workshop, and provides recommendations for integration of these techniques into future clinical trial design.

URI:

https://hdl.handle.net/10171/65651

DOI:

10.1016/j.bbmt.2017.12.774

Appears in Collections:

DA - CIMA - Inmunología e inmunoterapia - Inmunología del cáncer - Artículos de revista

Files in This Item: